What Fresofol Treats: Main Uses and Benefits

Fresofol is commonly used across several critical care domains and is commonly used in situations involving the need for general anaesthesia and sedation. Its application is generally considered relevant in clinical settings that involve acute or unstable symptom patterns.

This medicine is relevant for managing symptom clusters that become intense or disruptive, such as the need to abolish awareness, memory, and sensation for surgery, or the need to control severe agitation in critically ill patients. It is indicated for Induction and Maintenance of General Anaesthesia, providing procedural sedation for short diagnostic or surgical tests, and for continuous deep sedation in the Intensive Care Unit (ICU).

The medicine supports the patient during difficult episodes by easing distress and plays a role in managing acute phases.

“Fresofol helps to terminate the acute crisis in severe neurological events and supports the management of pronounced symptomatic distress in critical care.”

---

Quick Fact: Relief for Unconsciousness Requirement The medicine contributes to a generally quick return to consciousness, assisting with post-operative stabilization, a supportive benefit when symptoms interfere with daily functioning.

Fresofol (Propofol) eligibility is strictly defined by regulatory bodies based on patient characteristics and the clinical setting of use. Absolute contraindications prohibit its use in any individual with a known hypersensitivity to the active substance, Propofol, or to the emulsion components, such as soya or peanut. Furthermore, the medicine is contraindicated for continuous sedation in the Intensive Care Unit (ICU) for pediatric patients who are le 16 years of age.

General eligibility is established for adults for all labeled indications. In pediatric patients, eligibility for General Anaesthesia begins at ge 2 months for maintenance or ge 3 years for induction, depending on the specific regulatory source. Use is not recommended in newborn infants or for Monitored Anaesthesia Care (MAC) Sedation in children, as efficacy and safety have not been established.

Certain populations require restricted or conditional use. This includes elderly/geriatric patients and those classified as debilitated or ASA Physical Status III/IV. These groups are eligible only if the administration rate is reduced and special precautions are taken, as rapid administration is prohibited. For pregnancy, use is not recommended for obstetrical anesthesia due to the risk of neonatal depression.

Fresofol Interactions with other medicines and products

Official regulatory documents define the interaction profile of Fresofol (Propofol) based on its pharmacodynamic and pharmacokinetic properties, as well as specific administration requirements.

Interaction Scope

Property	Description
Medicinal product categories with documented interactions	Opioids, Sedative Agents, Other General Anesthetics, Analgesic Agents, Intravenous Lipid Solutions, Specific Muscle Relaxants (e.g., Suxamethonium, Atracurium, Mivacurium), Antiepileptic Medicines.
Specific interacting medicines (if explicitly listed)	Valproate, Apalutamide, Lidocaine, Suxamethonium, Neostigmine.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic Reinforcement (additive sedative and cardiorespiratory effects); Affects hepatic enzyme CYP2C9/10 metabolism (Apalutamide).
Timing-based interaction rules (if applicable)	Intravenous Line Flushing: Administration of certain muscle relaxants (Atracurium, Mivacurium) requires flushing the IV line used for Fresofol.
Population-specific interaction notes (if applicable)	Elderly, Debilitated, or ASA-PS III/IV Patients: Documented heightened cardiorespiratory risk when used concurrently with other depressant medications.
Interaction-related restrictions	Alcohol: Must be avoided due to officially stated stronger additive sedative effects. Soya and Peanut Products: Contraindicated due to documented hypersensitivity to excipients.

Interaction Classifications (High-Level)

Classification	Description
Interaction severity classification (as defined in official documents)	Contraindicated Combinations (Soya/Peanut hypersensitivity); Clinically Significant Interactions (Pharmacodynamic reinforcement; Exposure modification).
Interaction-context constraints (as defined in official documents)	Requirement to reduce the quantity of concurrently administered intravenous lipids to account for the Propofol formulation's lipid load.

Official Interaction Statements:

• Co-administration with Opioids, Sedative Agents, or Other General Anesthetics results in increased anesthetic, sedative, and cardiorespiratory depressant effects.
• Valproate is documented to increase the blood levels of Propofol, while Apalutamide is noted to decrease the effect by affecting hepatic metabolism.
• Administration with Lidocaine is officially documented to increase the risk of specific adverse events, including convulsions and changes in heart beat.
• Suxamethonium and Neostigmine are associated with depression of heart function when co-administered.

Connection to the overall interaction profile: Regulatory documents define Fresofol’s interaction structure primarily through two domains: Pharmacodynamic Reinforcement, which describes the official finding of additive depressant effects with other CNS agents, and Altered Exposure, which describes specific metabolic impacts that increase or decrease systemic concentration. This structure also incorporates mandatory timing-based procedural rules and specific allergy-related contraindications tied to the product's emulsion base.

Molecular Mechanism: Enhancing Central Inhibitory Signaling

The core mechanism involves Fresofol's highly specific action as a Positive Allosteric Modulator of the Gamma-aminobutyric acid type A ( GABA A) Receptor, the brain's primary inhibitory signaling conduit. By binding to allosteric sites on this receptor, Fresofol enhances the function of the inhibitory neurotransmitter GABA, resulting in a prolonged opening of the chloride ion channel. This surge of chloride ions drives the rapid and profound hyperpolarization of neurons.

Mechanistic Cascade and Systemic Depression

The widespread cellular hyperpolarization initiates a sequential mechanistic cascade resulting in the functional depression of integrated brain activity, particularly disrupting signal transmission across the thalamocortical pathways. This suppression of essential neural communication is the key physiological step resulting in the state of reduced consciousness. Fresofol also exerts secondary inhibitory actions by blocking other excitatory channels, such as Voltage-gated Na^+ Channels, contributing to the overall suppression of integrated central nervous system activity.

Secondary Effect: Modulation of Vascular Tone

Separate from its CNS action, the drug influences the cardiovascular system by inhibiting central sympathetic nerve outflow, causing a reduction in vasoconstrictive signaling. This systemic effect, combined with a direct inhibitory action on the heart muscle, leads to a decrease in both systemic vascular resistance and cardiac output.

Fresofol (propofol) is an injectable emulsion that is administered only in a clinical setting by healthcare professionals trained in anaesthesia or critical care, such as an anaesthetist or a specialist doctor in an intensive care unit. Facilities for monitoring breathing and circulation, and providing resuscitation, must be immediately available.

Administration Requirements

Procedure Aspect	Official Instruction
Route of Administration	Intravenous (IV) injection or continuous IV infusion.
Dosing Principle	Dosing is individualized and must be carefully titrated against the patient's immediate clinical response until the desired level of effect is achieved. Slower administration rates are used for elderly, debilitated, and high-risk patients (ASA III/IV).
Preparation	The product must be handled using strict aseptic technique immediately upon opening the vial, as the emulsion can support microbial growth. It is a single-use product, and any unused portion must be discarded.
Dilution	The emulsion can be administered undiluted. If dilution is necessary, it must only be done with 5% Dextrose Injection and not diluted to a concentration below 2 mg/mL.

Age-Specific Use and Duration

• Infants: The medication is not recommended for general anaesthesia induction in infants less than one month old.
• Children and Adolescents: It must not be used for sedation of patients aged 16 years or younger in the Intensive Care Unit (ICU) setting.
• ICU Sedation Duration: When used for sedation in ventilated adult patients in the ICU, the continuous infusion duration should generally not exceed seven days.

Infusion systems, tubing, and any unused product must be replaced or discarded after 12 hours of use to maintain sterility and safety.

Research Evidence / Overview of Studies for Fresofol (Propofol)

This overview summarizes the type of research that has been conducted on the active ingredient in Fresofol, Propofol, focusing on the structure of the evidence and what specific outcomes were examined. This is not clinical advice and should not replace a discussion with a healthcare professional.

---

Evidence for Use in General Anesthesia

The evidence base for the use of this medicine in general anesthesia (putting a patient fully to sleep for surgery) is largely derived from many Randomized Controlled Trials (RCTs), often summarized in Systematic Reviews and Meta-Analyses. These studies research examined how quickly the medicine caused patients to lose consciousness (induction time) and how quickly they woke up after the procedure was finished (emergence time). They also studies explored overall measurements related to maintaining the required depth of anesthesia throughout the procedure.

The findings describe patterns observed in the studies where loss of consciousness was measured as rapid. Studies also monitored measurements related to the time it took for patients to wake up and their initial recovery scores in the short-term. This research provides insight into short-term changes during the surgical procedure and the immediate time afterward.

However, the research largely focuses on the short-term intraoperative and immediate recovery outcomes. Long-term effects are not fully established, and there is limited information on how a patient's functional recovery or quality of life was observed in the months following a procedure under this agent. The results apply only to the populations studied, and findings may vary across studies due to the wide range of other anesthetic medicines used for comparison.

---

Evidence for Use in Procedural Sedation

The medicine was studied for its use in achieving procedural sedation—a relaxed, sleep-like state—for short diagnostic tests or minor procedures like endoscopies. Evidence comes from various RCTs and Observational Studies. These studies research examined outcomes reflecting daily functioning or activity level, such as the overall measurements for reaching the target sedation depth and the time it took for the patient to meet standard discharge criteria afterward.

The studies data show patterns related to outcomes for sedation for many short procedures. Findings describe patterns observed in the studies related to recovery times. Studies monitored when patients met standard discharge criteria. This research helps contextualize how patients reported their experience during the immediate recovery phase.

Despite this, the follow-up durations were limited, focusing mainly on the period from administration up to the patient’s discharge, and limited information for long-term outcomes exists. Furthermore, evidence quality varies across studies due to differences in how researchers defined and measured sedation, and the use of different pain-relieving medicines alongside the sedative.

---

Evidence for Continuous Deep Sedation in Critical Care

The use of this medicine for continuous deep sedation in the Intensive Care Unit (ICU) for patients on breathing machines was evaluated in RCTs and Prospective Cohort Studies, often summarized in Systematic Reviews and Meta-Analyses. Researchers primarily studies explored outcomes related to systemic or functional imbalance, such as the total duration a patient needed to remain on the mechanical ventilator and their overall length of stay in the ICU and hospital. Long-term outcomes, including all-cause survival (e.g., 28-day mortality), was observed in some studies.

The findings indicate that studies report how symptoms evolved in the observed populations when compared to other sedative types. The research contributes to understanding symptom patterns regarding how mechanical ventilation time and ICU stay durations were measured. However, the findings were mixed when examining long-term outcomes like survival, particularly across different patient groups (e.g., trauma patients versus cardiac surgery patients).

The certainty remains low for some of the longer-term outcomes because the subgroup findings are uncertain, and the complexity of the patients’ underlying critical illnesses acts as a major factor that can influence results. Research is ongoing to clarify findings across different sedative types for specific populations within the critical care setting.

---

Evidence in Specific Patient Populations

Research was studied for use in patient groups outside of the general adult population. For example, research has been conducted for both children (pediatric patients) and older adults in the context of both general anesthesia and procedural sedation. These studies research examined the specific measurements for loss of consciousness and emergence in these groups, particularly focusing on the data show patterns related to outcomes across different age ranges.

However, data for certain groups remain insufficient. Specifically, there is limited information for long-term outcomes in pediatric patients who receive continuous sedation for extended periods in the ICU. Similarly, while older adults was observed in many trials, subgroup findings are uncertain regarding the full range of specific age-related comorbidities.

---

Long-term Follow-up and Extended Outcomes

Research conducted and reported for regulatory purposes typically focuses on short-term outcomes—those measured during the procedure or in the immediate hours afterward. Outcomes reflecting daily functioning or activity level or the patient's neurological status months after receiving the medicine are not fully established.

Studies of extended duration, which would provide insight into the durability of recovery or any long-lasting effects, are limited. Therefore, long-term effects are not fully established, and the evidence largely helps show what has been observed so far in the acute setting, but not the chronic recovery path.

---

Research Gaps and Areas of Uncertainty

The research provides a necessary structure for understanding the medicine’s effects in the acute setting, but several research limitation frames exist. Evidence quality varies across studies, especially when comparing different sedative agents in the ICU, where the findings are often mixed. Follow-up durations were limited for most studies, meaning there is limited information for long-term outcomes regarding functional recovery and overall quality of life. Furthermore, comparative evidence remains limited for some of the less common uses, and subgroup findings are uncertain when examining patients with rare or severe comorbidities. This evidence highlights what is known — and what is still uncertain — about the use of this medicine.

Key Studies & References NICE Guideline NG45: Routine preoperative tests for elective surgery

Common questions about Fresofol (FAQ)

Q: How quickly does Fresofol start working (onset) and how fast does it wear off (emergence)?

Official product information indicates that the drug works rapidly. The onset of deep sleep, or hypnosis, typically begins within 40 seconds after an intravenous injection is started. Following short procedures or use for continuous sedation at recommended durations, patients generally experience a prompt and rapid awakening.

Q: What does the dosage principle 'titrated' mean?

Regulatory documents describe the dosage principle 'titrated' as the method by which the medicine is given. The dosage is carefully adjusted against the patient’s immediate clinical response until the desired level of effect is reached. An adequate interval must be allowed between these adjustments to assess the full effect of the medicine.

Q: How does Fresofol's effect on the cardiovascular system change my blood pressure?

Official information states that this medicine frequently causes changes in the cardiovascular system. It can lead to a decrease in blood pressure (hypotension) and may cause a slower heart rate (bradycardia). These effects are considered dose-dependent.

Q: What specific medical procedures is Fresofol typically used for sedation?

According to official therapeutic indications, Fresofol is used to induce and maintain general anesthesia for surgery. It is also used to provide sedation for various short diagnostic or surgical procedures, and to provide continuous deep sedation for critically ill, mechanically ventilated adults in the Intensive Care Unit (ICU).

Q: How is Fresofol prepared before administration, and can it be diluted?

Official labeling confirms that the emulsion can be administered undiluted. The official label specifies that if dilution is necessary, it must only be done using 5% Dextrose Injection and cannot be diluted to a concentration below 2 mg/mL.

Q: Is there a specific antidote for a Fresofol overdose or severe sedation?

No specific antidote or reversal agent exists to counteract the effects of a Fresofol overdose. In the event of an overdose, the treatment outlined in regulatory documents focuses on supportive care to address cardiorespiratory depression, which may involve artificial ventilation and measures to support blood pressure.

Q: What happens if I receive other medicines like opioids or sedatives with Fresofol?

Official drug interaction statements warn of Pharmacodynamic Reinforcement (additive effects). Co-administration with opioids, sedatives, or other anesthetic agents results in an increased anesthetic, sedative, and cardiorespiratory depressant effect. For this reason, the dosage of Fresofol is often required to be reduced when used alongside these other agents.

How to Store and Dispose of Fresofol

Fresofol (Propofol) injectable emulsion must be stored according to strict regulatory requirements to maintain its stability. Storage is mandated at Controlled Room Temperature, specifically between 20°C to 25°C (68°F to 77°F), and the product must be protected from light. It is prohibited to freeze the emulsion.

Stability and Handling

Fresofol is a single-use parenteral product. Aseptic technique must be maintained during handling. Once the vial is opened or spiked, any unused portion must be discarded within 12 hours due to the risk of microbial contamination. Vials must be shaken well before use and visually inspected for separation.

Final Disposal

The medicine must be stored out of the sight and reach of children. Unused or expired Fresofol must be discarded according to the specific local regulations and institutional policies for pharmaceutical waste.